Sep. 9 at 8:48 AM
$AYTU very sorry about your loss, dolphinguy. But:
Q3 2025 Highlights
Net revenue increased 32% to
$18.5 million versus
$14.0 million in Q3 fiscal 2024.
ADHD Portfolio (Adzenys XR-ODT® and Cotempla XR-ODT®) net revenue increased 25% to
$15.4 million versus
$12.3 million in Q3 fiscal 2024.
Pediatric Portfolio (Karbinal® ER, Poly-Vi-Flor® and Tri-Vi-Flor®) net revenue increased 77% to
$3.1 million versus
$1.7 million in Q3 fiscal 2024.
Net income of
$4.0 million, or
$0.65 and
$0.21 net income per share basic and diluted, respectively, compared to a net loss of
$2.9 million, or
$0.52 net loss per share basic and diluted in Q3 fiscal 2024.
Adjusted EBITDA was
$3.9 million compared to
$0.9 million in Q3 fiscal 2024.
Cash and cash equivalents were
$18.2 million at March 31, 2025.
